Brought to you by 
Existing investors return for AC Immune's CHF40mm Series C round
20 Jun 2012
Executive Summary
Existing shareholders have invested CHF40mm ($37mm) in the Series C financing for AC Immune SA (uses drug discovery platforms SupraAntigen and Morphomers to develop vaccines, antibodies, and small molecules for Alzheimer's disease). The Swiss biotech will draw the funds in two tranches. The latest round brings the total invested in AC Immune since inception to CHF64mm.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Existing investors return for AC Immune's CHF40mm Series C round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice